17.71
3.95 (28.71%)
AIStockmoo 评分
| 价值 30% | -3.9 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 资本回报低于资本成本。资本回报下降。 参考 | |
| 时机 30% | -2.2 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年呈上升趋势。股价远低于52周高点。 参考 | |
| K线形态 参考 | NA |
| 您持有期的趋势 参考 | NA |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | 0.2 |
| 内部交易活动 参考 | NA |
| 机构在最新13F申报中净+0.15%的股份:35家增持,18家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化-5.0%,回补天数12.5天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短期趋势向上,中期和长期向下。短期动能下降。 参考 | |
| 股价处于支撑位与阻力位之间。支撑与阻力水平趋升。 参考 | |
| 最终评分 | -2.42 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Greenwich LifeSciences, Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| GLSI | - | - | - | 70.35 |
| GLTO | 2 B | - | - | - |
| IPA | 96 M | - | - | 5.98 |
| ACIU | - | - | - | 6.56 |
| DNLI | - | - | - | 3.24 |
| GHRS | - | - | - | 3.65 |
|
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual’s immune system to selectively attack cancer cells to inhibit the spread of cancer. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 52.30% |
| 机构持股比例 | 9.47% |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 13.79%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 35 | 189,628 |
| 减持 | 18 | 137,114 |
| 新建仓 | 4 | 18,060 |
| 清仓 | 7 | 48,039 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 1,578,166 | 12.5 |
| 15 Oct 2026 | 1,552,366 | 10.7 |
| 30 Sep 2026 | 1,580,950 | 11.4 |
| 15 Sep 2026 | 1,631,150 | 19.8 |
| 31 Aug 2026 | 1,660,969 | 11.4 |
| 14 Aug 2026 | 1,593,720 | 13.3 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
Greenwich LifeSciences Gears Up For Two Breast Cancer Vaccine Presentations — Retail Says ‘Peptide Vaccine Works’ After SLS Trial Success
Greenwich said two research abstracts related to its experimental breast cancer drug were accepted for the San Antonio Breast Cancer Symposium, scheduled for December 8 to 11… |
| 17 Nov 2026 | Yahoo Finance |
Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026
STAFFORD, Texas, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast… |
| 15 Sep 2026 | Yahoo Finance |
3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest. |
投资组合